Given that increased CCL2 and CXCL10 expression has been reported in PD brains and cerebrospinal fluid [51,53], our findings suggest that ATM inhibition may modulate inflammatory signaling pathways to mitigate neuroinflammation. This evidence concerns the gene CCL2 and Parkinson disease.